Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer

G. Lainakis; Nikos Antoniou; G. Alivizatos; Chrisofos Michael; Mitsoyiannis Iraklis; Livadas Konstantinos; Varkarakis Ioannis; Katsifotis Harilaos; Meletios A Dimopoulos; Aristotelis Bamias

doi:10.1016/j.urology.2008.02.048

Related publications

Article2011

Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer

Ioannis Mountzios, Evangelos Bournakis, Eleni Efstathiou, Andreas Varkaris, Sijin Wen, Michael Chrisofos, Charalambos Deliveliotis, Christos Alamanis, Ιoannis Anastasiou, C. Constantinides, Alexandra Karadimou, Marinos Tsiatas, Christos Papadimitriou, Aristotelis Bamias, Meletios A Dimopoulos

Article1997

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

Meletios A Dimopoulos, C Panopoulos, Christina Bamia, C. Deliveliotis, G. Alivizatos, D Pantazopoulos, C. Constantinidis, A. Kostakopoulos, Ioannis Kastriotis, Anastasios Zervas, Gerasimos Aravantinos, C Dimopoulos

Article2006

Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma

George Bozas, Aristotle Bamias, Vassiliki Koutsoukou, Eleni Efstathiou, Dimitra Gika, Christos Papadimitriou, Meletios A Dimopoulos

Article2004

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

Raymond P. Abratt, D. Brune, Meletios A Dimopoulos, J. Kliment, J. Breza, Fp Selvaggi, Philippe Beuzeboc, Tomasz Demkow, Stéphane Oudard

Article2021

UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).

Arun Azad, Nattakorn Dhiantravan, Louise Emmett, Anthony M. Joshua, Ian Vela, David A. Pattison, Roslyn J. Francis, Scott Williams, Shahneen Sandhu, Ian D. Davis, Nitika Neha, Mathias Bressel, Declan G. Murphy, Michael S. Hofman